Analyze the mechanism of action of maribasvir/yitazhi

Maribavir (Maribavir) is an innovative antiviral drug designed to treat cytomegalovirus (CMV) infection or reactivation in transplant patients. Its mechanism of action is completely different from traditional antiviral drugs, and it is a specific inhibitor targeting the CMV UL97 protein kinase. UL97 is a viral protein that is critical for CMV virus replication and plays a key role in viral DNA packaging, gene transcription regulation and virion maturation. Maribavir selectively binds to and inhibits the activity of UL97 kinase, blocking the key replication link of the virus in host cells, thereby effectively inhibiting virus proliferation.

Different from traditional drugs that act onDNA polymerase (such as ganciclovir, foscarnet, etc.), maribavir does not directly interfere with the host or viral DNA replication process, but inhibits the UL97-mediated viral protein phosphorylation activity to prevent the viral nucleocapsid from successfully entering the nucleus. This unique mechanism avoids the problem of cross-resistance with traditional anti-CMV drugs and greatly reduces the toxicity to the bone marrow and hematopoietic system, making it an important breakthrough in the treatment of CMV infection after transplantation.

In addition, maribabavir can also prevent the formation of viral envelope and the spread of viral particles between cells. This "multi-target blocking" effect makes it more effective in treating drug-resistant or refractory CMV infections. Overseas studies have shown that maribavir still has inhibitory activity against UL97 and UL54 drug-resistant strains, which means that maribavir provides a new treatment approach for immunocompromised patients who have been receiving antiviral drugs for a long time.

In terms of pharmacological properties, maribavir has good oral absorption, high bioavailability, and can quickly reach effective concentrations in the body. Its metabolism is mainly through the liverCYP3A4 pathway, which does not significantly affect the blood concentration of commonly used immunosuppressants such as tacrolimus or cyclosporine, and has good drug compatibility.

Reference materials:https://www.livtencity.com/